Chlamydia

The U.S. Preventive Services Task Force said today it recommends chlamydia and gonorrhea screening in all sexually active women aged younger than 24 years and women aged 25 years or older with an increased risk for infection.

The CDC on Thursday published updated clinical guidelines for the treatment of STIs amid a sustained national increase in cases of chlamydia, gonorrhea and syphilis.

A week-long regimen of doxycycline was superior to a single-dose of azithromycin for the treatment of rectal chlamydia among men who have sex with men, or MSM, according to study results.

The CDC announced a record number of chlamydia, gonorrhea and syphilis cases in the United States in 2019. It was the top story in infectious disease last week.

The United States reported more than 2.5 million cases of chlamydia, gonorrhea and syphilis in 2019, setting a record for STDs for a sixth consecutive year, the CDC said.

The U.S. Preventive Services Task Force issued a draft recommendation encouraging physicians to screen for chlamydia and gonorrhea in all sexually active women aged 24 years and younger.

Despite national guidelines recommending that sexually active people with HIV be tested annually for STIs, many transgender women with HIV are not tested for syphilis, chlamydia or gonorrhea, researchers reported.

After hitting record highs for years before the COVID-19 pandemic, reported cases of chlamydia, gonorrhea and syphilis dipped below projections for 2020 in the United States, researchers reported.

HIV and STI testing outside of clinics increases uptake with minimal risks, a systematic review and meta-analysis showed.

Vaginal swab samples collected by patients performed similarly to lab-based molecular diagnostics for chlamydia and gonorrhea testing, therefore supporting the use of a new 30-minute point-of-case assay, according to findings published in JAMA Network Open.